NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP
Nyxoah SA NYXH
6 fiscal years on record · EUR · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
€10.0M
▲ 121.6% vs FY2024
EPS · FY25
€-2.36
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-111.0%
Net margin · FY25
-899.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 10.0M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 899 cents on every revenue dollar this year.
Per share
EUR -2.36
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-111.0%
Return on equity, FY2025
ROE
Operating margin-833.2%
Net margin-899.1%
Return on assets-65.1%
Each EUR of equity lost 111 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+170.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+48.1%
+170.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years+94.7%
Change, 10 years—
The share count grew 95% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 118.5M
total assets, end of FY2025
Total assetsEUR 118.5M
EquityEUR 49.1M
CashEUR 30.0M
Current ratio1.25×
Equity funds 41% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2025
2024
2023
2022
2021
2020
Revenue €B
0.0
0.0
0.0
0.0
0.0
0.0
Operating income €B
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA €B
·
·
·
·
·
·
Income tax €B
0.0
0.0
−0.0
0.0
0.0
0.0
Net income €B
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted €
−2.36
−1.81
−1.54
−1.21
−1.16
−0.68
Dividend / sh €
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−111.0
−56.1
−39.6
−23.2
−18.6
·
Shares out B
0.04
0.04
0.03
0.03
0.03
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 22
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed